Yuanxin Liang, MD, PhD
Assistant Professor of PathologyCards
About
Research
Publications
2026
150 Pathologic Characterization of Non-Mass Enhancement Lesions of the Breast in MRI-Guided Core Biopsies
Jordan T, Liang Y, Krishnamurti U, Lewin J, Zhan H. 150 Pathologic Characterization of Non-Mass Enhancement Lesions of the Breast in MRI-Guided Core Biopsies. Laboratory Investigation 2026, 106: 104429. DOI: 10.1016/j.labinv.2025.104429.Peer-Reviewed Original Research204 Estimating Breast Tumor Size from Histologic Section Involvement: A Correlative Study with Imaging and Gross Pathology
Salehiazar S, Moideen P, Zhan H, Ai D, Krishnamurti U, Liang Y. 204 Estimating Breast Tumor Size from Histologic Section Involvement: A Correlative Study with Imaging and Gross Pathology. Laboratory Investigation 2026, 106: 104483. DOI: 10.1016/j.labinv.2025.104483.Peer-Reviewed Original Research193 Can Histologic Features of Flat Epithelial Atypia Distinguish Cases with and without Co-Existing Ductal Carcinoma In Situ (DCIS)?
Perera N, Zhan H, Ai D, Du J, Krishnamurti U, Liang Y. 193 Can Histologic Features of Flat Epithelial Atypia Distinguish Cases with and without Co-Existing Ductal Carcinoma In Situ (DCIS)? Laboratory Investigation 2026, 106: 104472. DOI: 10.1016/j.labinv.2025.104472.Peer-Reviewed Original Research149 Largest Ductal Diameter as a Histopathologic Predictor of DCIS Extent in Resection Specimens
Jordan T, Liang Y, Krishnamurti U, Zhan H. 149 Largest Ductal Diameter as a Histopathologic Predictor of DCIS Extent in Resection Specimens. Laboratory Investigation 2026, 106: 104428. DOI: 10.1016/j.labinv.2025.104428.Peer-Reviewed Original Research
2025
Invasive breast carcinoma in a patient with PHTS: a case report
Zhan H, Fischbach N, Lynch M, Liang Y, Krishnamurti U, Cohen P. Invasive breast carcinoma in a patient with PHTS: a case report. Diagnostic Pathology 2025, 20: 120. PMID: 41107919, PMCID: PMC12532417, DOI: 10.1186/s13000-025-01715-1.Peer-Reviewed Original ResearchConceptsPTEN hamartoma tumor syndromeAtypical ductal hyperplasiaHamartoma tumor syndromeTumor syndromeFamily historyBilateral palpable breast massesFocal atypical ductal hyperplasiaFamily history of cancerInvasive breast carcinomaPalpable breast massesEctopic breast tissueBloody nipple dischargeAxillary lymph nodesGermline pathogenic variantsHistory of cancerCase presentationWeInvasive carcinomaBreast carcinomaDuctal hyperplasiaMastectomy specimensNipple dischargeRight breastBenign papillomasMultiple biopsiesPapillary proliferationInfrequent HPV Infection in Colorectal Neuroendocrine Carcinoma: Molecular and Histologic Characteristics
Wang X, Zhong M, Zhang X, Liang Y. Infrequent HPV Infection in Colorectal Neuroendocrine Carcinoma: Molecular and Histologic Characteristics. Diagnostics 2025, 15: 2569. PMID: 41153242, PMCID: PMC12562367, DOI: 10.3390/diagnostics15202569.Peer-Reviewed Original ResearchHigh-risk human papillomavirusSmall cell neuroendocrine carcinomaCell neuroendocrine carcinomaColorectal neuroendocrine carcinomaNeuroendocrine carcinomaPlatinum-based chemotherapyHigh-risk HPVHigh risk human papillomavirus statusHigh-risk human papillomavirus testingAssociated with high-risk human papillomavirusOncogenic mutationsMethods:Molecular profilingResults:Rectal neuroendocrine carcinomaComprehensive molecular profilingOptimal treatment strategyLong-term survivorsHPV infectionAggressive tumorsP16 expressionHuman papillomavirusClinical outcomesLonger survivalSurrogate markerInterobserver agreement and histologic analysis of atypical ductal hyperplasia bordering on ductal carcinoma in situ: A multi-institutional study
Korie U, Ai D, Podany P, Zhang H, Zhan H, Kahila M, Colon-Cartagena L, Wei S, Sun H, Du J, Krishnamurti U, Liang Y. Interobserver agreement and histologic analysis of atypical ductal hyperplasia bordering on ductal carcinoma in situ: A multi-institutional study. American Journal Of Clinical Pathology 2025, 164: 704-711. PMID: 40994034, DOI: 10.1093/ajcp/aqaf088.Peer-Reviewed Original ResearchConceptsDuctal carcinoma in situAtypical ductal hyperplasiaCarcinoma in situSpindle-shaped nucleiAssociated with carcinomaIndividual histologic featuresHistological featuresInterobserver agreementDuctal hyperplasiaBreast pathologistsBiopsy casesCases of atypical ductal hyperplasiaLow-grade ductal carcinoma in situEpithelial cellsClinical follow-up dataLesion extentHistological analysisDiagnostic gray zoneMulti-institutional studyVariable interobserver agreementFollow-up dataModerate to substantial agreementDuct involvementHistologic reviewRadiological findingsEstrogen receptor conversion in bone, liver and lung metastases from breast cancer
Podany P, Zhan H, Ai D, Krishnamurti U, Liang Y. Estrogen receptor conversion in bone, liver and lung metastases from breast cancer. Pathology - Research And Practice 2025, 275: 156222. PMID: 40967162, DOI: 10.1016/j.prp.2025.156222.Peer-Reviewed Original ResearchER conversionPrimary tumorTumor gradeGrade of primary tumorAssociated with worse prognosisMetastasis to boneBreast cancer treatmentMetastatic sitesER-positiveMedian survivalTP53 mutationsLiver metastasesPR positivityPIK3CA mutationsReceptor conversionClinicopathological factorsLung metastasesWorse prognosisNo significant differenceTumor typesBreast cancerGenetic alterationsMetastasisPatient managementTumorPTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence
Zhan H, Antony V, Tang H, Theriot J, Liang Y, Hui P, Krishnamurti U, DiGiovanna M. PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence. Breast Cancer Research And Treatment 2025, 211: 441-447. PMID: 40063317, DOI: 10.1007/s10549-025-07660-3.Peer-Reviewed Original ResearchConceptsPten inactivating mutationsBreast cancerER+/HER2- tumorsRecurrent tumorsER+/HER2- breast cancer patientsInactivating mutationsAssociated with worse clinical outcomesTreatment historyER+/HER2- breast cancerTriple negative phenotypeBreast cancer recurrenceBreast cancer patientsHormone receptor lossResultsThe average timeHR+ tumorsDistant recurrenceHR statusER expressionRecurrent diseaseTumor histologyTumor recurrenceHER2 expressionHormone independencePatient ageClinicopathological characteristics116 Pathological and Molecular Characterization of Estrogen Receptor-Positive/HER2-Negative de novo Metastatic Breast Cancer
Babb P, Theriot J, Liang Y, Cartagena L, Buza N, Krishnamurti U, Zhan H. 116 Pathological and Molecular Characterization of Estrogen Receptor-Positive/HER2-Negative de novo Metastatic Breast Cancer. Laboratory Investigation 2025, 105: 102340. DOI: 10.1016/j.labinv.2024.102340.Peer-Reviewed Original Research